Vis enkel innførsel

dc.contributor.authorHolm, Aki
dc.contributor.authorKirkegaard, Hans
dc.contributor.authorTaccone, Fabio Silvio
dc.contributor.authorSøreide, Eldar
dc.contributor.authorGrejs, Anders Morten
dc.contributor.authorToome, Valdo
dc.contributor.authorHassager, Christian
dc.contributor.authorRasmussen, Bodil S.
dc.contributor.authorLaitio, Timo
dc.contributor.authorStorm, Christian
dc.contributor.authorHästbacka, Johanna
dc.contributor.authorSkrifvars, Markus B.
dc.date.accessioned2022-03-29T11:03:10Z
dc.date.available2022-03-29T11:03:10Z
dc.date.created2022-01-22T21:33:13Z
dc.date.issued2021
dc.identifier.issn2639-8028
dc.identifier.urihttps://hdl.handle.net/11250/2988302
dc.description.abstractObjectives: To investigate rebound hyperthermia following targeted temperature management after cardiac arrest and its impact on functional outcome. Design: Post hoc analysis. Setting: Ten European ICUs. Patients: Patients included in the time-differentiated therapeutic hypothermia in out-of-hospital cardiac arrest survivors trial treated with targeted temperature management at 33°C for 48 or 24 hours. Favorable functional outcome was defined as a Cerebral Performance Category of 1 or 2 at 6 months. Interventions: None. Measurements and main results: Of 338 included patients, 103 (30%) experienced rebound hyperthermia defined as a maximum temperature after targeted temperature management and rewarming exceeding 38.5°C. Using multivariate logistic regression analysis, increasing age (odds ratio, 0.97; 95% CI, 0.95–0.99; p = 0.02) and severe acute kidney injury within 72 hours of ICU admission (odds ratio, 0.35; 95% CI, 0.13–0.91; p = 0.03) were associated with less rebound hyperthermia, whereas male gender (odds ratio, 3.94; 95% CI, 1.34–11.57; p = 0.01), highest C-reactive protein value (odds ratio, 1.04; 95% CI, 1.01–1.07; p = 0.02), and use of mechanical chest compression during cardiopulmonary resuscitation (odds ratio, 2.00; 95% CI, 1.10–3.67; p = 0.02) were associated with more rebound hyperthermia. Patients with favorable functional outcome spent less time after rewarming over 38.5°C (2.5% vs 6.3%; p = 0.03), 39°C (0.14% vs 2.7%; p < 0.01), and 39.5°C (0.03% vs 0.71%; p < 0.01) when compared with others. Median time to rebound hyperthermia was longer in the unfavorable functional outcome group (33.2 hr; interquartile range, 14.3–53.0 hr vs 6.5 hr; interquartile range, 2.2–34.1; p < 0.01). In a predefined multivariate binary logistic regression model, rebound hyperthermia was associated with decreased odds of favorable functional outcome (odds ratio, 0.42; 95% CI, 0.22–0.79). Conclusions: One-third of targeted temperature management patients experience rebound hyperthermia, and it is more common in younger male patients with an aggravated inflammatory response and those treated with a mechanical chest compression device. Later onset of rebound hyperthermia and temperatures exceeding 38.5°C associate with unfavorable outcome.en_US
dc.language.isoengen_US
dc.publisherWolters Kluweren_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleFactors Associated With Rebound Hyperthermia After Targeted Temperature Management in Out-of-Hospital Cardiac Arrest Patients: An Explorative Substudy of the Time-Differentiated Therapeutic Hypothermia in Out-of-Hospital Cardiac Arrest Survivors Trialen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 the authorsen_US
dc.source.articlenumbere0458en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1097/CCE.0000000000000458
dc.identifier.cristin1987966
dc.source.journalCritical Care Explorationsen_US
dc.identifier.citationCritical Care Explorations. 2021, 3 (7), e0458.en_US
dc.source.volume3en_US
dc.source.issue7en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal